Virax Biolabs Group (VRAX) Fundamental Analysis: Revenue, Earnings & Valuation

0.46 / 10

Underperform

Fundamental rating is Underperform (0.5/10). Asset‑MV and Profit‑MV show modest strength, while Cash‑MV, Cash‑UP, ROA and ROE are negative, placing the stock in low‑quality groups that historically deliver negative monthly returns. Overall fundamentals are weak and defensive.

Analysis Checks(3/10)

ROA (%)

Value-101.88

Score0/3

Weight34.57%

1M Return-6.12%

Annualized return on equity (%)

Value-109.58

Score1/3

Weight15.66%

1M Return-2.02%

Profit-MV

Value0.41

Score2/3

Weight-31.60%

1M Return3.26%

Cash-UP

Value-0.01

Score2/3

Weight28.82%

1M Return-3.92%

Annualized net profit margin on total assets (%)

Value-101.88

Score0/3

Weight34.57%

1M Return-6.12%

ROE (diluted) (%)

Value-106.41

Score1/3

Weight10.98%

1M Return-1.41%

Asset-MV

Value-0.48

Score3/3

Weight-51.00%

1M Return4.79%

ROE (%)

Value-109.58

Score1/3

Weight15.66%

1M Return-2.02%

Cash-MV

Value-0.09

Score1/3

Weight24.85%

1M Return-3.56%

Net profit / Total profit (%)

Value97.80

Score1/3

Weight17.49%

1M Return-2.37%

Is VRAX undervalued or overvalued?

VRAX scores 0.46/10 on fundamentals and holds a Premium valuation at present. Backed by its -44.40% ROE, -189348.33% net margin, -0.24 P/E ratio, 0.27 P/B ratio, and 53.26% earnings growth, these metrics solidify its Underperform investment rating.